Showing 3841-3850 of 4165 results for "".
- Ripple Therapeutics Appoints Jonathan Talamo, MD, to Chair of the Boardhttps://modernod.com/news/ripple-therapeutics-appoints-jonathan-talamo-md-to-chair-of-the-board/2481265/Ripple Therapeutics announced that Jonathan Talamo, MD, has been appointed as the new Chair of its Board of Directors. Dr. Talamo is internationally known as an experienced surgeon and thought leader in ophthalmology. Following 25 years in clinical practice, Dr. Talamo s
- Kinarus Therapeutics Provides Strategic Updatehttps://modernod.com/news/kinarus-therapeutics-provides-strategic-update/2481226/Kinarus Therapeutics reiterated its plans to focus on clinical trials in wet age-related macular degeneration (AMD) and idiopathic pulmonary fibrosis, and to refocus its capital resources and financing efforts to drive these programs. Following the discontinuation of the phase 2 KINETIC
- Neurotech Pharmaceuticals Announces Positive Phase 3 Topline Results for NT-501 Implant in Macular Telangiectasia Type 2https://modernod.com/news/neurotech-pharmaceuticals-announces-positive-phase-3-topline-results-for-nt-501-implant-in-macular-telangiectasia-type-2/2481217/Neurotech Pharmaceuticals announced positive topline results in two replicative phase 3 clinical trials with their investigational encapsulated cell therapy (ECT) for the treatment of Macular telangiectasia type 2 (MacTel), an orphan, slowly progressive degenerative disease of the macula that res
- Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470https://modernod.com/news/nicox-reports-achieving-primary-objective-in-mont-blanc-the-first-phase-3-glaucoma-trial-for-ncx-470/2481209/Nicox SA announced that once daily dosing of NCX 470 0.1% met the primary objective of noninferiority in lowering IOP compared to the standard of care, latanoprost 0.005%, in the 691-patient Mont Blanc phase 3 clinical trial in patients with open-angle glaucoma or ocular hypertension.</
- Vyluma Announces Positive Results From Phase 3 CHAMP Study of NVK002 for Treatment of Myopia Progression in Childrenhttps://modernod.com/news/vyluma-announces-positive-results-from-phase-3-champ-study-of-nvk002-for-treatment-of-myopia-progression-in-children/2481205/Vyluma announced topline results from its phase 3 CHAMP (Childhood Atropine for Myopia Progression) clinical study. Analysis of this multicenter, international study, performed after 3 years of treatment and follow up, demonstrates strong safety and efficacy for NVK002 as a potential treatment fo
- Genentech Voluntarily Recalls Susvimo Ocular Implant for Wet AMDhttps://modernod.com/news/genentech-voluntarily-recalls-susvimo-ocular-implant-for-wet-amd/2481185/Roche and Genentech announced a voluntarily recall of the Susvimo (ranibizumab injection) ocular implant for wet AMD, citing a manufacturing problem with the device. In addition, the companies announced that new implantations, including in ongoing global clinical trials, have been paused.
- Nicox Provides Third Quarter 2022 Financial and Business Highlightshttps://modernod.com/news/nicox-provides-third-quarter-2022-financial-and-business-highlights/2481179/Nicox SA provided financial and business highlights for the third quarter of 2022 for Nicox SA and its subsidiaries (the “Nicox Group”) and confirmed timing for the upcoming NCX 470 Mont Blanc Phase 3 clinical trial milestone. Key Upcoming Milestone
- Clearside: Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platformhttps://modernod.com/news/clearside-positive-data-presentations-at-aao-annual-meeting-demonstrate-utility-and-versatility-of-clearside-biomedicals-proprietary-suprachoroidal-space-platform/2481151/Clearside Biomedical announced that clinical data from multiple internal and partnered programs were presented at the recent 2022 Annual Meeting of the American Academy of Ophthalmology (AAO), the world's largest association of eye physicians and surgeons. “These data presenta
- EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathyhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-2-pavia-trial-of-eyp-1901-for-the-treatment-of-non-proliferative-diabetic-retinopathy/2481131/EyePoint Pharmaceuticals announced that the first patient has been dosed in the phase 2 PAVIA clinical trial of EYP-1901, a potential sustained delivery intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment targeting non-proliferative diabetic retinopathy (NPDR).
- Atsena Therapeutics Announces Late-Breaker Presentation at the AAO Annual Meetinghttps://modernod.com/news/atsena-therapeutics-announces-late-breaker-presentation-at-the-aao-annual-meeting/2481107/Atsena Therapeutics announced that data from the phase 1/2 clinical trial of ATSN-101 will be presented in a late breaking developments session during the Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO 2022), which is being held Sept